Study of orforglipron for heart and kidney health.
Treatments studied
Part of Brain & nervous system, Heart & circulation, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests if orforglipron can reduce the risk of heart attack, stroke, or kidney failure in people with heart disease or chronic kidney disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with heart disease (like a previous heart attack or blocked arteries) or chronic kidney disease.
- You do not have type 1 diabetes.
- You have not had a major heart event (like a heart attack or stroke) in the last 2 months.
- Your heart failure is not severe (Class IV is the most severe type).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational medicine called elecoglipron for people with chronic kidney disease. It aims to see if it can improve kidney health compared to a placebo (inactive pill) and may be an option for those already on standard blood pressure and kidney protective medications.
This study tests HRS-7535, a new oral tablet that may help protect kidneys in people with chronic kidney disease. GLP-1 medications were originally developed for diabetes but may also benefit kidney function and overall health.
This trial tests a new oral medication called orforglipron to see if it can improve walking distance in people with peripheral artery disease (PAD) who have leg pain when walking. It may be a good option if you have PAD and your walking is limited by leg cramping, not other health issues.
This trial tests an investigational medication (orforglipron) to see if it helps people with knee arthritis lose weight. You may qualify if you have overweight or obesity and have tried dieting before without lasting success.
This study looks at how your genes affect your response to a diabetes medication called orforglipron. You will stop your usual diabetes pills for 5 days, then take the study drug and have a meal test to see how your blood sugar and body respond.
This trial tests an investigational oral medication to help Chinese adults with overweight or obesity, plus related health issues, lose weight. It focuses on improving weight loss and overall health in this group.
Hear when a new Atherosclerosis Cardiovascular Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.